CN117737018A - Olefine aldehyde reductase mutant, rhamnosidase mutant, three-enzyme expression strain and application thereof - Google Patents
Olefine aldehyde reductase mutant, rhamnosidase mutant, three-enzyme expression strain and application thereof Download PDFInfo
- Publication number
- CN117737018A CN117737018A CN202410172865.XA CN202410172865A CN117737018A CN 117737018 A CN117737018 A CN 117737018A CN 202410172865 A CN202410172865 A CN 202410172865A CN 117737018 A CN117737018 A CN 117737018A
- Authority
- CN
- China
- Prior art keywords
- mutant
- hesperidin
- enal
- reductase
- rhamnosidase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010053754 Aldehyde reductase Proteins 0.000 title description 4
- 102100027265 Aldo-keto reductase family 1 member B1 Human genes 0.000 title description 3
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims abstract description 62
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims abstract description 62
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims abstract description 62
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims abstract description 62
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims abstract description 62
- 229940025878 hesperidin Drugs 0.000 claims abstract description 62
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims abstract description 62
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims abstract description 55
- 102000004316 Oxidoreductases Human genes 0.000 claims abstract description 51
- 108090000854 Oxidoreductases Proteins 0.000 claims abstract description 51
- 102000004190 Enzymes Human genes 0.000 claims abstract description 36
- 108090000790 Enzymes Proteins 0.000 claims abstract description 36
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 claims abstract description 36
- 108010004539 Chalcone isomerase Proteins 0.000 claims abstract description 34
- 239000013612 plasmid Substances 0.000 claims abstract description 33
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 claims abstract description 30
- -1 hesperetin dihydrochalcone glucoside Chemical class 0.000 claims abstract description 28
- 229930182478 glucoside Natural products 0.000 claims abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 238000006243 chemical reaction Methods 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 108010056771 Glucosidases Proteins 0.000 claims description 4
- 102000004366 Glucosidases Human genes 0.000 claims description 4
- 230000003197 catalytic effect Effects 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 14
- 230000000052 comparative effect Effects 0.000 description 10
- 241001052560 Thallis Species 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 6
- 238000006555 catalytic reaction Methods 0.000 description 6
- 235000005513 chalcones Nutrition 0.000 description 6
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- RWKSTZADJBEXSQ-UHFFFAOYSA-N 3-(3-hydroxy-4-methoxyphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O RWKSTZADJBEXSQ-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010044879 alpha-L-rhamnosidase Proteins 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001329 FEMA 3811 Substances 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical group OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002207 flavanone derivatives Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940089953 neohesperidin dihydrochalcone Drugs 0.000 description 1
- 235000010434 neohesperidine DC Nutrition 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
Abstract
The invention discloses an enal reductase mutant, a rhamnosidase mutant and a three-enzyme expression bacteriumThe strain and the application thereof can overcome the technical problem of insufficient activity of natural enal reductase, and the reaction condition is mild, so that the strain and the application thereof can be used for preparing hesperidin dihydrochalcone composition from hesperidin. The conversion rate for preparing hesperidin dihydrochalcone compositions is higher when the enal reductase mutant and the chalcone isomerase mutant are used in combination. The three enzyme expression strain can simultaneously express chalcone isomerase CmCHI M Mutants, enal reductase OR mutants and rhamnosidase RhaB2 mutants by chalcone isomerase CmCHI M The recombinant plasmids of the mutants and the enal reductase mutants and the plasmid of the rhamnosidase mutant are used for preparing the hesperetin dihydrochalcone glucoside composition by catalyzing and converting hesperidin by a double plasmid expression system.
Description
Technical Field
The invention relates to the technical field of enzyme engineering, in particular to an enal reductase mutant, a rhamnosidase mutant, a three-enzyme expression strain and application thereof.
Background
Neohesperidin dihydrochalcone (NHDC), although having a sweetness of 1800 times that of sucrose, has a bad afterbitter taste like licorice, plus a solubility in water of only 0.5 g/L, which limits its use to some extent. This results in the need for the use of neohesperidin dihydrochalcone in the food, pharmaceutical daily use, feed and other industries to be formulated with other sweeteners or taste modifiers. While hesperetin dihydrochalcone glucoside (HCG) is a low calorie non-nutritive sweetener, although its sweetness is about 300-500 times that of sucrose, it is pure in sweetness, free from bitter and aftertaste, and has fruit flavor.
The current preparation method of dihydrochalcone mainly uses a chemical method, uses flavanone as a substrate, and carries out hydrogenation under the action of alkaline conditions and metal catalysts such as platinum, palladium and the like to finally generate the dihydrochalcone. The chemical method is easy to pollute the environment, contains byproducts, has potential safety hazard when being used for preparing food additives, has mild reaction conditions, is environment-friendly and safe, has extremely high specificity, is an ideal preparation way, but has no report on the biosynthesis of dihydrochalcone series products such as hesperidin dihydrochalcone glucoside, hesperetin dihydrochalcone and the like by a one-step method at present.
alpha-L-rhamnosidase (EC 3.2.1.40) is a class of glycoside hydrolase with wide application prospects, widely exists in plants, animals and microorganisms, can break glycosidic bonds formed by reacting alcoholic hydroxyl groups with hemiacetals in an exo-or endo-manner, and plays an important role in the synthesis and hydrolysis of glycoconjugates and saccharides in organisms. The enal reductase (2-alkenal reductase) can catalyze the hydrogenation reduction of unsaturated double bonds in the enal group to generate saturated aldehyde, and then other aldehyde reductases act to generate carbon dioxide and water, so that the reaction of the high-activity unsaturated double bonds with intracellular small molecular substances is greatly reduced. The natural alpha-L-rhamnosidase and enal reductase have insufficient activity, and the reaction environment is difficult to meet the optimal conditions of the natural enzymes.
Disclosure of Invention
In order to overcome the defects in the prior art, one of the purposes of the invention is to provide an enal reductase mutant which can solve the problem of poor catalytic conversion effect of the existing enal reductase.
The second object of the invention is to provide an application of enal reductase, which is combined with chalcone isomerase mutant, and uses hesperidin as raw material to prepare hesperidin dihydrochalcone composition, and has high conversion rate.
It is a further object of the present invention to provide a strain expressing three enzymes, which can express chalcone isomerase, enal reductase and rhamnosidase simultaneously.
The fourth object of the invention is to provide an application of a three-enzyme expression strain, which can be used for producing hesperidin monoglucoside dihydrochalcone composition.
One of the purposes of the invention is realized by adopting the following technical scheme:
an enal reductase OR mutant, wherein the enal reductase mutant has an amino acid sequence shown in SEQ ID NO:1, the glutamine at position 662 is mutated to cysteine and the aspartic acid at position 462 is mutated to glutamic acid. The mutant was designated OR-Q662A-D462E.
The second purpose of the invention is realized by adopting the following technical scheme:
the enal reductase mutant is used for reducing hesperidin to prepare hesperidin dihydrochalcone.
Preferably, the enal reductase mutant is combined with a chalcone isomerase mutant to catalyze the conversion of hesperidin to prepare the hesperidin dihydrochalcone composition.
The third purpose of the invention is realized by adopting the following technical scheme:
a three-enzyme expression strain is an enal reductase OR mutant, a rhamnosidase RhaB2 mutant and a chalcone isomerase CmCHI M A plasmid-expressing strain of the mutant; wherein the chalcone isomerase CmCHI M The amino acid sequence of the mutant is shown in SEQ ID NO:9, tryptophan at position 120 of chalcone isomerase is mutated into histidine, leucine at position 183 is mutated into tyrosine, and the nucleotide sequence is shown in SEQ ID NO:10 is shown in the figure; the amino acid sequence of the rhamnosidase mutant is shown as SEQ ID NO:5 to isoleucine at position 227 of the rhamnosidase enzyme. So the mutant is mutant RhaB2-W227I. The rhamnosidase mutant is used for preparing hesperetin dihydrochalcone glucoside.
Namely, the three-enzyme expression strain can simultaneously express the chalcone isomerase mutant CmCHI M An enal reductase OR, which is OR wild type OR a mutant thereof, and a rhamnosidase RhaB2, which RhaB2 is RhaB2 wild type or mutant thereof.
The fourth purpose of the invention is realized by the following technical scheme:
the use of a trisaccharide expression strain in the preparation of hesperidin dihydrochalcone compositions.
Preferably, the hesperidin dihydrochalcone composition is hesperidin dihydrochalcone glucoside, and the preparation method comprises the following steps: preparing the three-enzyme expression strain into whole-cell enzyme liquid, then adding glucosidase, hesperidin and buffer solution, and reacting at 25-35 ℃ to obtain the hesperetin dihydrochalcone glucoside. The three-enzyme expression strain can be used for preparing the hesperetin dihydrochalcone glucoside under mild conditions, so that the technical problem that the natural enzyme reaction environment is difficult to meet is solved.
The invention actually uses the strain to simultaneously detect the chalcone isomerase CmCHI M The ability of the enal reductase OR, rhamnosidase RhaB2, to directly convert hesperidin into a hesperetin dihydrochalcone glucoside composition by expressing the three enzymes simultaneously. Specifically, it is the enal reductase and chalcone isomerase therein that converts hesperidin to a hesperidin dihydrochalcone composition, and then the rhamnosidase enzyme converts hesperidin dihydrochalcone to a hesperetin dihydrochalcone glucoside composition.
Specifically, the construction method of the three-enzyme expression strain comprises the following steps:
(1) Construction of chalcone isomerase CmCHI M And recombinant plasmids of the enal reductase OR and the vector to obtain recombinant plasmids of the chalcone isomerase-enal reductase; wherein the vector is Escherichia coli, namely pET28a-CmCHI M -an OR plasmid;
(2) Constructing a rhamnosidase plasmid; wherein the vector is escherichia coli and is marked as pET32a-RhaB2 plasmid;
(3) pET28a-CmCHI obtained in step (1) M Construction and selection of chalcone isomerase mutant CmCHI in the-OR plasmid M Compositions with enal reductase mutants OR-Q662A-D462E; is denoted as CmCHI M -OR-Q662A-D462E；
(4) Constructing and screening a rhamnosidase mutant RhaB2-W227I in the rhamnosidase plasmid obtained in the step (2);
(5) And co-converting the composition of the chalcone isomerase mutant and the enal reductase mutant and the rhamnosidase mutant into a carrier, and screening positive transformants in a culture medium to obtain the three-enzyme expression strain.
It should be noted that the chalcone isomerase CmCHI M The combination of the vectors of the enolase OR and the rhamnosidase RhaB2 comprises, but is not limited to, the above method, and the combination of the three enzymes by adopting different vectors can be also carried out, OR the combination of the three enzymes can be carried out firstly, then the combination of the three enzymes and the last combination can be carried out. The combination mode of the three enzymes does not influence the expression effect of the three enzymes.
Preferably, in the step (1), the construction method of the recombinant chalcone isomerase-enal reductase plasmid comprises the following steps: the method comprises the steps of taking a synthetic chalcone isomerase gene with an amino acid sequence shown as SEQ ID NO. 1 and a nucleotide sequence shown as SEQ ID NO. 2 as a template, synthesizing two primers shown as SEQ ID NO. 3 and SEQ ID NO. 4 in a sequence table, respectively adding two digestion sites of Nde I and EcoR I at two ends of the synthesized primers, carrying out PCR, separating a PCR product by agarose gel electrophoresis, connecting the recovered PCR product into plasmids of chalcone isomerase and a vector, screening positive transformants, and obtaining the recombinant plasmid of the chalcone isomerase-enal reductase.
Preferably, in the step (2), the method for constructing the rhamnosidase plasmid comprises the following steps: the method comprises the steps of taking a synthetic gene rhamnosidase RhaB2 with an amino acid sequence shown as SEQ ID NO. 5 and a nucleotide sequence shown as SEQ ID NO. 6 as a template, synthesizing two primers shown as SEQ ID NO. 7 and SEQ ID NO. 8 in a sequence table, respectively adding EcoR I and Not I enzyme cutting sites at two ends of the synthesized primers, carrying out PCR, separating PCR products by agarose gel electrophoresis, connecting the recovered PCR products into a pET32a vector, screening out positive transformants, and obtaining recombinant plasmids named pET32a-RhaB2 plasmids.
Compared with the prior art, the invention has the beneficial effects that:
(1) The enal reductase mutant can overcome the technical problem of insufficient activity of natural enal reductase, has mild reaction conditions, and can be used for preparing hesperidin dihydrochalcone composition from hesperidin. The conversion rate for preparing hesperidin dihydrochalcone compositions is higher when the enal reductase mutant and the chalcone isomerase mutant are used in combination.
(2) The rhamnosidase mutant can overcome the technical problem of insufficient activity of natural rhamnosidase, has mild reaction conditions, can be used for converting hesperidin dihydrochalcone into a hesperetin dihydrochalcone glucoside composition, and has high conversion rate.
(3) The three-enzyme expression strain of the invention can simultaneously express the chalcone isomerase CmCHI M Mutants, enal reductase OR mutants and rhamnosidase RhaB2 mutants by chalcone isomerase CmCHI M The recombinant plasmids of the mutant and the enal reductase OR mutant and the plasmid of the rhamnosidase RhaB2 mutant are used for preparing the hesperidin dihydrochalcone glucoside composition by catalyzing and converting hesperidin by a double-plasmid expression system.
(4) The application of the three-enzyme expression strain can directly convert hesperidin into a hesperetin dihydrochalcone glucoside composition. Specifically, it is the enal reductase and chalcone isomerase therein that converts hesperidin to a hesperidin dihydrochalcone composition, and then the rhamnosidase enzyme converts hesperidin dihydrochalcone to a hesperetin dihydrochalcone glucoside composition. Fills the blank that hesperidin is not taken as a raw material at the present stage, and hesperidin is directly catalyzed and converted into hesperidin dihydrochalcone, hesperetin dihydrochalcone glucoside and hesperetin dihydrochalcone by a biological method.
Drawings
FIG. 1 is a diagram of a three-dimensional structural model of a chalcone isomerase-enal reductase combination mutant;
FIG. 2 is a diagram of a three-dimensional structural model of a rhamnosidase mutant;
FIG. 3 is a schematic diagram showing the enzyme activities of a chalcone isomerase-enal reductase combination mutant and a wild-type enal reductase;
FIG. 4 is a chromatographic analysis of the rhamnosidase mutant and wild-type rhamnosidase reaction product;
FIG. 5 is a chromatographic analysis of the catalytic preparation of hesperetin dihydrochalcone glucoside by a three enzyme expression strain;
FIG. 6 is a diagram of a chromatographic analysis of the catalytic preparation of hesperetin dihydrochalcone by a three enzyme expression strain.
Detailed Description
The present invention will be further described with reference to the accompanying drawings and detailed description, wherein it is to be understood that, on the premise of no conflict, the embodiments described below or technical features may be arbitrarily combined to form new embodiments. The following are specific examples of the present invention, in which raw materials, equipment, etc. used are available in a purchase manner except for specific limitations.
In the following examples, the specific conditions are specified by the conventional experimental conditions or the experimental conditions suggested by the manufacturer, and the various reagents involved in the examples are commercially available unless otherwise specified. The experimental method of molecular biology, which is not specifically described in this example, can be referred to the "guidelines for molecular cloning experiments".
Example 1
Relates to the construction of related plasmids of the patent:
recombinant plasmids pET28a-CmCHI of chalcone isomerase and enal reductase and escherichia coli M Construction of-OR
The synthetic gene of the olefine aldehyde reductase OR mutant with the amino acid sequence shown as SEQ ID NO. 1 and the nucleotide sequence shown as SEQ ID NO. 2 is used as a template to synthesize two primers shown as SEQ ID NO. 3 and SEQ ID NO. 4 in a sequence table, and two ends of the synthesized primers are respectively added withNde IAndEcoR IPCR was performed at two cleavage sites. The DNA polymerase is KOD DNA polymerase with high fidelity of Bao bioengineering Co., ltd. The PCR amplification procedure was: 94 ℃ for 2min; 15s at 94 ℃, 30s at 58 ℃ and 2min at 72 ℃ for 35 cycles; the temperature was reduced to 10℃for 10min at 72 ℃. The DNA was recovered from the agarose gel using Axygen Gel Extraction Kit (AEYGEN Co.). Separating PCR product by agarose gel electrophoresis, and recovering PCR productT4 DNA ligase ligation Using thermo Fisher CoNde IAndEcoR Idouble-enzyme-cut pET28a-CmCHI M In a carrier. Positive transformants were selected on Kan-resistant medium and the recombinant plasmid obtained was designated pET28a-CmCHI M -OR. Wherein, the amino acid sequence of the chalcone isomerase mutant is shown in SEQ ID NO:9, the nucleotide sequence of which is shown as SEQ ID NO: shown at 10.
Construction of the (two) rhamnosidase plasmid pET32a-RhaB2
Two primers of SEQ ID NO. 7 and SEQ ID NO. 8 in a sequence table are synthesized by taking a rhamnosidase RhaB2 mutant with an amino acid sequence shown as SEQ ID NO. 5 and a nucleotide sequence shown as SEQ ID NO. 6 as a template, and two ends of the synthesized primers are respectively added withEcoR IAndNot IPCR was performed at two cleavage sites. Separating PCR product by agarose gel electrophoresis, and connecting the recovered PCR product with T4 DNA ligaseEcoR IAndNot Iin the double digested pET32a vector. Positive transformants were selected on medium containing Amp resistance and the recombinant plasmid obtained was designated pET32a-RhaB2.
Example 2
Chalcone isomerase-enal reductase (CmCHI) M -OR) construction of mutants and rhamnosidase RhaB2 mutants:
and (3) carrying out artificial intelligent modeling on OR by using alpha fold2, and evaluating the model to obtain a reliable three-dimensional structure model according to the evaluation of the scoring standard, wherein the three-dimensional structure model is shown in figure 1. Multiple active sites are obtained by simulating the docking ligand, and the mutant is constructed for enzyme activity detection and screening to obtain the mutant CmCHI M -OR-Q662A-D462E, i.e.glutamine at position 662 is mutated to cysteine and aspartic acid at position 462 is mutated to glutamic acid.
And carrying out artificial intelligent modeling on RhaB2 by using alpha Fold2, and evaluating the model to obtain a reliable three-dimensional structure model according to the evaluation of the scoring standard, wherein the three-dimensional structure model is shown in figure 2. Multiple active sites are obtained through simulating a docking ligand, a mutant is constructed, enzyme activity detection is carried out on the mutant, and the mutant RhaB2-W227I is obtained through screening, namely, the 227 th tryptophan is mutated into isoleucine.
Example 3
Mutant CmCHI M Comparison of the wild-type enzyme activities with OR-Q662A-D462E:
mutant CmCHI M When the OR-Q662A-D462E and the wild type are respectively cultured in LB culture medium containing Kan until the OD600 is 0.6-1.0, 0.2 mmol/L IPTG is added to induce 18 h at 20 ℃, and then the steps of removing supernatant, washing thalli with water, re-suspending thalli and the like are carried out by centrifugation, so that 2 parts of whole cell crude enzyme liquid with equal concentration is obtained. Finally, hesperidin with the final concentration of 2mM is added, the whole cell catalytic reaction is carried out at 30 ℃ for 24h, and the conversion rate of hesperidin dihydrochalcone is detected by HPLC (high Performance liquid chromatography), as shown in figure 3, and the result shows that CmCHI M The enzyme activity of the-OR-Q662A-D462E is improved, the conversion rate is improved from 8.7 percent to 75.4 percent, and the conversion rate is improved by more than 8.6 times compared with a wild strain.
Example 4
Comparison of mutant rhaB2-W227I with wild type enzyme activity:
culturing mutant RhaB2-W227I and wild rhamnosidase RhaB2 respectively in LB culture medium containing Kan to OD 600 When the concentration is 0.6-1.0, 0.2 mmol/L of IPTG is added to induce the mixture at 20 ℃ for 18 h, and then the mixture is subjected to the steps of centrifugation to remove supernatant, water washing and re-suspension of thalli to obtain 2 parts of whole-cell crude enzyme liquid with equal concentration. Finally, the hesperidin dihydrochalcone with the final concentration of 2mM is added, the whole cell catalytic reaction is carried out at 30 ℃ for 24h, and the conversion rate of hesperetin dihydrochalcone glucoside is detected by HPLC, as shown in figure 4, the result shows that the enzyme activity of RhaB2-W227I is improved, the conversion rate is improved from 11.5% to 81.3%, and the conversion rate is improved by more than 7 times compared with the wild rhamnosidase RhaB2 strain.
Example 5
Combined mutant plasmid of enal reductase mutant and chalcone isomerase mutant (pET 28a-CmCHI M Construction and use of double plasmid expression strains of the OR-Q662A-D462E) and the rhamnosidase mutant plasmid (pET 32A-RhaB 2-W227I):
pET28a-CmCHI M Co-transforming-OR-Q662A-D462E and pET32A-RhaB2-W227I into BL21, screening positive transformant with culture medium containing Amp and Kan double resistance, obtaining double plasmid expression strain named COR, namely threeEnzyme expression strain.
Culturing COR in LB culture medium containing Amp and Kan until OD600 is 0.6-1.0, adding 0.2 mmol/L IPTG to induce 18 h at 20 ℃, and performing steps such as centrifugation to remove supernatant, water washing thalli, re-suspending thalli and the like to obtain the whole cell crude enzyme liquid. Finally, the hesperidin with the final concentration of 2mM is added, the whole-cell catalytic reaction is carried out at 30 ℃ for 24h, and the conversion rate of hesperidin dihydrochalcone and hesperetin dihydrochalcone glucoside is detected by HPLC, as shown in figure 5, the result shows that the hesperidin can be converted into hesperetin dihydrochalcone glucoside by a COR strain in one step, and the conversion rate can reach 71.5%.
Example 6
Application of COR in combination with commercial glucosidase:
200U/mL commercial glucosidase and 2mM hesperidin are added into whole-cell enzyme solution expressed by COR as raw materials, pH 4.6 citric acid-phosphate is taken as buffer solution, and the mixture is reacted for 24 hours at 30 ℃, as shown in FIG. 6, and the conversion rate of the hesperetin dihydrochalcone glucoside is 69.7 percent through detection.
Comparative example 1
Comparative example 1 differs from example 5 in that: the strain of comparative example 1 only expressed rhamnosidase and chalcone isomerase, i.e. the strain was composed of only rhamnosidase RhaB2 and chalcone isomerase mutant CmCHI M The combined plasmids are transformed. Culturing the strain in LB culture medium containing Kan until the OD600 is 0.6-1.0, adding 0.2 mmol/L of IPTG for induction at 20 ℃ for 18 h, centrifuging to remove supernatant, washing thalli, re-suspending thalli and other steps to obtain whole cell crude enzyme liquid, adding hesperidin with the final concentration of 2mM, and carrying out whole cell catalytic reaction at 30 ℃ for 24h, wherein the conversion rate of the hesperetin dihydrochalcone glucoside is 0%.
Comparative example 2
Comparative example 2 differs from example 5 in that: the strain of comparative example 2 only expresses the chalcone isomerase mutant and the enal reductase, i.e., the strain is composed of only the chalcone isomerase mutant CmCHI M The plasmid combined with the enal reductase OR mutant was transformed and the bacterium was cultured in LB medium containing Kan to an OD600 of 0.And (3) when 6-1.0, adding 0.2 mmol/L IPTG to induce 18-h at 20 ℃, centrifuging to remove supernatant, washing thalli, re-suspending thalli and the like to obtain whole-cell crude enzyme liquid, finally adding hesperidin with the final concentration of 2mM, and carrying out whole-cell catalytic reaction at 30 ℃ for 24-h, wherein the conversion rate of the hesperidin dihydrochalcone glucoside is 0%.
Comparative example 3
Comparative example 3 differs from example 5 in that: the strain of comparative example 3 only expresses rhamnosidase and enal reductase, i.e. it is only transformed with a plasmid of the combination of rhamnosidase mutant RhaB2 and enal reductase OR mutant. The strain is cultured in LB culture medium containing Kan to OD 600 When the concentration is 0.6-1.0, 0.2 mmol/L of IPTG is added to induce 18 h at 20 ℃, then the steps of centrifugation, supernatant removal, water washing, bacterial body resuspension and the like are carried out to obtain whole-cell crude enzyme liquid, finally, hesperidin with the final concentration of 2mM is added, and the whole-cell catalytic reaction is carried out at 30 ℃ for 24h, wherein the conversion rate of the hesperetin dihydrochalcone glucoside is 0%.
In summary, as shown in examples 5 and comparative examples 1 to 3, when only one or two of chalcone isomerase, enal reductase and rhamnosidase are expressed in the strain, it is impossible to convert hesperidin to hesperidin dihydrochalcone glucoside. Because chalcone isomerase must be used in combination with enal reductase to convert hesperidin to hesperidin dihydrochalcone, whereas rhamnosidase can only convert hesperidin dihydrochalcone to hesperidin dihydrochalcone hesperetin dihydrochalcone glucoside. Therefore, the three enzymes can be combined to convert the hesperidin into the hesperidin dihydrochalcone glucoside.
The above embodiments are only preferred embodiments of the present invention, and the scope of the present invention is not limited thereto, but any insubstantial changes and substitutions made by those skilled in the art on the basis of the present invention are intended to be within the scope of the present invention as claimed.
Claims (6)
1. An enal reductase mutant, which is characterized in that the enal reductase mutant has an amino acid sequence shown in SEQ ID NO:1, the glutamine at position 662 is mutated to cysteine and the aspartic acid at position 462 is mutated to glutamic acid.
2. Use of the enal reductase mutant according to claim 1 for preparing hesperidin dihydrochalcone by reducing hesperidin.
3. Use of an enal reductase mutant according to claim 2 for the preparation of hesperidin dihydrochalcone by reduction of hesperidin, wherein the enal reductase mutant is combined with a chalcone isomerase mutant for the catalytic conversion of hesperidin to prepare a hesperidin dihydrochalcone composition.
4. A three-enzyme expression strain, characterized in that the strain is a plasmid expression strain of the enal reductase mutant, the rhamnosidase mutant, the chalcone isomerase mutant of claim 1; wherein, the amino acid sequence of the chalcone isomerase mutant is shown in SEQ ID NO:9, the nucleotide sequence of which is shown as SEQ ID NO:10 is shown in the figure; the amino acid sequence of the rhamnosidase mutant is shown as SEQ ID NO:5 to isoleucine at position 227 of the rhamnosidase enzyme.
5. Use of the three enzyme expression strain of claim 4 for the preparation of hesperidin dihydrochalcone compositions.
6. Use of the three enzyme expression strain according to claim 5 for the preparation of hesperidin dihydrochalcone composition, wherein the hesperidin dihydrochalcone composition is hesperetin dihydrochalcone glucoside, a preparation method thereof comprising the steps of: preparing the three-enzyme expression strain into whole-cell enzyme liquid, then adding glucosidase, hesperidin and buffer solution, and reacting at 25-35 ℃ to obtain the hesperetin dihydrochalcone glucoside.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410172865.XA CN117737018B (en) | 2024-02-07 | 2024-02-07 | Olefine aldehyde reductase mutant, rhamnosidase mutant, three-enzyme expression strain and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410172865.XA CN117737018B (en) | 2024-02-07 | 2024-02-07 | Olefine aldehyde reductase mutant, rhamnosidase mutant, three-enzyme expression strain and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117737018A true CN117737018A (en) | 2024-03-22 |
| CN117737018B CN117737018B (en) | 2024-05-03 |
Family
ID=90283577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410172865.XA Active CN117737018B (en) | 2024-02-07 | 2024-02-07 | Olefine aldehyde reductase mutant, rhamnosidase mutant, three-enzyme expression strain and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117737018B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108138151A (en) * | 2015-06-05 | 2018-06-08 | 埃沃尔瓦公司 | The biosynthesis of Phenylpropanoid Glycosides class and dihydro Phenylpropanoid Glycosides analog derivative |
| CN114164161A (en) * | 2022-02-15 | 2022-03-11 | 佛山市汇腾生物技术有限公司 | Double-enzyme co-expression strain for producing neohesperidin and construction method and application thereof |
| WO2022184248A1 (en) * | 2021-03-03 | 2022-09-09 | Symrise Ag | Biocatalytical production of dihydrochalcones |
| US20230279451A1 (en) * | 2019-09-27 | 2023-09-07 | Symrise Ag | Methods for the biocatalytical manufacturing of dihydrochalcones |
| CN116904490A (en) * | 2023-06-26 | 2023-10-20 | 佛山市汇腾生物技术有限公司 | Method for biosynthesis of dihydrochalcone, transgenic microorganism and construction method thereof |
| CN116926051A (en) * | 2023-09-19 | 2023-10-24 | 佛山市汇腾生物技术有限公司 | Chalcone isomerase mutant and preparation method and application thereof |
| CN117467627A (en) * | 2023-12-26 | 2024-01-30 | 佛山市汇腾生物技术有限公司 | Olefine aldehyde reductase mutant and encoding gene and application thereof |
-
2024
- 2024-02-07 CN CN202410172865.XA patent/CN117737018B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108138151A (en) * | 2015-06-05 | 2018-06-08 | 埃沃尔瓦公司 | The biosynthesis of Phenylpropanoid Glycosides class and dihydro Phenylpropanoid Glycosides analog derivative |
| US20230279451A1 (en) * | 2019-09-27 | 2023-09-07 | Symrise Ag | Methods for the biocatalytical manufacturing of dihydrochalcones |
| WO2022184248A1 (en) * | 2021-03-03 | 2022-09-09 | Symrise Ag | Biocatalytical production of dihydrochalcones |
| CN114164161A (en) * | 2022-02-15 | 2022-03-11 | 佛山市汇腾生物技术有限公司 | Double-enzyme co-expression strain for producing neohesperidin and construction method and application thereof |
| CN116904490A (en) * | 2023-06-26 | 2023-10-20 | 佛山市汇腾生物技术有限公司 | Method for biosynthesis of dihydrochalcone, transgenic microorganism and construction method thereof |
| CN116926051A (en) * | 2023-09-19 | 2023-10-24 | 佛山市汇腾生物技术有限公司 | Chalcone isomerase mutant and preparation method and application thereof |
| CN117467627A (en) * | 2023-12-26 | 2024-01-30 | 佛山市汇腾生物技术有限公司 | Olefine aldehyde reductase mutant and encoding gene and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| "NCBI Reference Sequence: WP_118702673.1", NCBI REFERENCE SEQUENCE: WP_118702673.1, 2 February 2024 (2024-02-02) * |
| MANDE, S.S.等: "Protein-protein interactions in the pyruvate dehydrogenase multienzyme complex: dihydrolipoamide dehydrogenase complexed with the binding domain of dihydrolipoamide acetyltransferase", 《STRUCTURE》, vol. 4, no. 3, 31 December 1996 (1996-12-31), pages 277 - 286 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117737018B (en) | 2024-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10683525B2 (en) | Method for producing 2-O-glyceryl-alpha-D-glucopyranoside | |
| JP6929499B2 (en) | Enzymatic hydrolysis of disaccharides and oligosaccharides using alpha-glucosidase enzyme | |
| JP2019047797A (en) | Method for obtaining 1-kestose | |
| JP4998991B2 (en) | Method for producing cellulase | |
| CN108350474B (en) | Method for small molecule glycosylation | |
| CN117737018B (en) | Olefine aldehyde reductase mutant, rhamnosidase mutant, three-enzyme expression strain and application thereof | |
| CN113337495A (en) | Method for improving sialic acid yield and application | |
| CN114164161B (en) | Double-enzyme co-expression strain for producing neohesperidin and construction method and application thereof | |
| CN109415747B (en) | Preparation method of enzyme modified stevioside, enzyme for preparation and application | |
| Lu et al. | Recent Progress on galactooligosaccharides synthesis by microbial β-galactosidase | |
| Letsididi et al. | Lactulose production by a thermostable glycoside hydrolase from the hyperthermophilic archaeon Caldivirga maquilingensis IC‐167 | |
| CN115449514A (en) | Beta-1, 2-glycosyltransferase and application thereof | |
| EP2186904B1 (en) | Method for producing glucose derivatives | |
| JP4272377B2 (en) | New uses of uridine diphosphate glucose 4-epimerase | |
| Shimosaka et al. | Analysis of essential carboxylic amino acid residues for catalytic activity of fungal chitosanases by site-directed mutagenesis | |
| US6841368B1 (en) | Enzymatic production of difructose dianhydride IV from sucrose and relevant enzymes and genes coding for them | |
| US20200208184A1 (en) | Methods of Producing 5-Ketofructose | |
| JP5391510B2 (en) | Protein having β-glucosidase activity and use thereof | |
| WO2023169200A1 (en) | Recombinant yeast and application thereof | |
| CN118185887A (en) | CO2Activation of key enzymes and uses thereof | |
| EP3460067A1 (en) | Process for enzymatic oxidation of linear carbohydrates | |
| CN116949116A (en) | Efficient sucrose phosphorylase and application thereof in production of glyceroglycosides | |
| JP5605331B2 (en) | Protein having β-glucosidase activity and use thereof | |
| CN117946990A (en) | UDP-glycosyltransferase and application thereof in preparing high-purity rebaudioside M | |
| CN116656643A (en) | Acetyltransferase mutant and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |